Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
2.
Prostate Cancer Prostatic Dis ; 25(4): 741-748, 2022 04.
Article in English | MEDLINE | ID: mdl-35091711

ABSTRACT

OBJECTIVE: Treatment efficacy of androgen deprivation therapy with radical prostatectomy for intermediate- to high-risk prostate cancer is less well-studied. The NEAR trial is a single-arm, phase II investigation of neoadjuvant apalutamide monotherapy and radical prostatectomy (RP) in the treatment of D'Amico intermediate- and high-risk prostate cancer (NCT03124433). MATERIALS AND METHODS: Patients with histologically-proven, D'Amico intermediate- to high-risk prostate adenocarcinoma received apalutamide 240 mg once-daily for 12 weeks followed by RP + /-lymphadenectomy. Primary outcome was pathological complete response (pCR) rate. Secondary outcomes included rate of biochemical response (defined by PSA < 0.03 ng/mL at week 24 from starting apalutamide without subsequent PSA relapse), treatment-related adverse events, and RP complication rates. Correlative biomarker analyses were performed to examine for molecular predictors of treatment responses. RESULTS: From 2017 to 2019, 30 patients were recruited, of which 20 and 10 were high and intermediate risk, respectively; 25 completed treatment as per-protocol. We did not observe any pCR on trial; median reduction of cancer burden was 41.7% (IQR: 33.3%-60.0%). 18 out of 25 patients were classified as having a biochemical response (4 did not achieve PSA of <0.03 ng/mL at week 24 and 3 developed PSA relapse subsequently). Dry skin (N = 16; 53.3%), fatigue (N = 10; 33.3%) and skin rash (N = 9; 30.0%) were the most common adverse events, and there was no major peri-operative complication. We observed an association between tumours of low androgen receptor activity and PAM50 basal status with biochemical non-responders, albeit these molecular phenotypes were not associated with pathological response. CONCLUSIONS: A 12-week course of neoadjuvant apalutamide prior to RP did not meet the primary endpoint of pCR in this trial. Tumours with low androgen receptor activity or of the PAM50 basal subtype may have a reduced response to apalutamide.


Subject(s)
Prostate-Specific Antigen , Prostatic Neoplasms , Male , Humans , Prostate/pathology , Neoadjuvant Therapy/methods , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/surgery , Prostatic Neoplasms/pathology , Androgen Antagonists/therapeutic use , Receptors, Androgen , Neoplasm Recurrence, Local/surgery , Prostatectomy/methods
3.
BMJ Case Rep ; 20132013 Jan 09.
Article in English | MEDLINE | ID: mdl-23307454

ABSTRACT

This is a case report of prostate carcinoma metastasising to a renal oncocytoma. The report demonstrates the unusual presentation of metastases from a common cancer to a common benign tumour, and reviews the rare phenomenon of tumour-to-tumour metastases.


Subject(s)
Adenoma, Oxyphilic/secondary , Carcinoma, Renal Cell/pathology , Kidney Neoplasms/pathology , Neoplasms, Second Primary , Prostatic Neoplasms/secondary , Adenoma, Oxyphilic/diagnosis , Adenoma, Oxyphilic/surgery , Aged , Carcinoma, Renal Cell/diagnostic imaging , Carcinoma, Renal Cell/surgery , Diagnosis, Differential , Humans , Kidney Neoplasms/diagnosis , Kidney Neoplasms/diagnostic imaging , Kidney Neoplasms/secondary , Kidney Neoplasms/surgery , Male , Nephrectomy , Prostatic Neoplasms/diagnosis , Radiography
4.
Int J Colorectal Dis ; 26(3): 275-94, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21279370

ABSTRACT

AIM: Sacral nerve stimulation (SNS) has recently been used in the management of faecal incontinence (FI). This study compared SNS to conservative management with regards to functional and quality of life outcomes. METHODS: Meta-analysis of studies published between 1995 and 2008 on SNS for FI was performed. Outcomes evaluated were functional, physiological and quality of life. A random-effects model was used and sensitivity analyses performed. Subgroup analyses were performed on age and sphincter status. RESULTS: Thirty-four studies were included, reporting on 944 patients undergoing peripheral nerve evaluation; 665 underwent permanent SNS. Weekly incontinence episodes (weighted mean difference [WMD] -6.83; 95% confidence intervals [CI] -8.05, -5.60; p < 0.001) and incontinence scores (WMD -10.57; 95% CI -11.89, -9.24; p < 0.001) were significantly reduced with SNS; ability to defer defecation (WMD 7.99 min; 95% CI 5.93, 10.05; p < 0.001) was increased. Most SF-36 and FIQL domains improved following SNS, and mean anal pressures increased significantly (p < 0.001). Results remained consistent on sensitivity analysis. The under-56 years age group showed smaller functional but greater physiological and quality of life improvements. Results were similar between sphincter intact and impaired subgroups. The complication rate was 15% for permanent SNS, with 3% resulting in permanent explantation. CONCLUSION: SNS results in significant improvements in objective and subjective measures for faecally incontinent patients.


Subject(s)
Electric Stimulation Therapy/methods , Fecal Incontinence/physiopathology , Fecal Incontinence/therapy , Sacrum/innervation , Sacrum/physiopathology , Anal Canal/physiopathology , Humans , Manometry , Middle Aged , Publication Bias , Quality of Life , Rectum/physiopathology , Treatment Outcome
5.
Int J Colorectal Dis ; 25(10): 1193-200, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20640432

ABSTRACT

AIMS: Known collectively as serrated polyps, hyperplastic polyps (HP), sessile serrated adenomas (SSA/SSP) and traditional serrated adenoma (TSA) may represent a spectrum of increasing malignant potential with characteristic immunological markers. There is increasing evidence that HP, SSA/SSP and TSA are biologically different and are likely to represent a spectrum along the serrated polyp pathway. Although there is general consensus about the diagnostic features of serrated polyps, the morphological differences between the categories are often subtle. This study compares the expression of p53 and P504S among serrated polyps. Sixty seven randomly selected biopsies (n = 59) and resection specimens (n = 8) histologically diagnosed for SSA/SSP, TSA and HP (19, 30 and 18 specimens, respectively) were obtained. METHODS AND RESULTS: There was a significant difference in p53 (P < 0.001) and P504S (P < 0.001) immunopositivity and distribution among the serrated polyps. In particular, there is diffuse expression p53 and P504S in TSA compared to HP and SSA/SSP where p53 and P504S expression was more frequently confined to the lower 1/3 of the crypts. In addition, percentage of cells expressing p53 and p504S expression was higher in TSA than those of HP and SSA/SSP. CONCLUSION: Immunostains, p53 and P504S, may be useful adjuncts to morphological diagnosis of serrated polyps.


Subject(s)
Adenomatous Polyps/diagnosis , Colonic Neoplasms/diagnosis , Colonic Polyps/diagnosis , Racemases and Epimerases/analysis , Tumor Suppressor Protein p53/analysis , Adult , Aged , Aged, 80 and over , Biomarkers , Female , Gene Expression Regulation, Neoplastic , Humans , Male , Middle Aged
6.
Br J Haematol ; 141(6): 771-81, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18371110

ABSTRACT

Chronic myelomonocytic leukaemia (CMML) is a clonal disorder with myelodysplastic/myeloproliferative features. Its diagnosis is based on the presence of peripheral blood monocytosis and bone marrow aspirate findings, according to World Health Organization criteria. However, bone marrow trephine biopsy (BMTB) features characteristic of CMML have not been adequately investigated. We studied BMTB in 20 cases of CMML-1 and three cases of CMML-2 and compared with ten cases of polycythaemia vera, ten cases of chronic myeloid leukaemia (chronic phase) and ten cases of florid myeloid hyperplasia (MH). Furthermore, we evaluated the use of CD34, CD117 and CD68 (PGM-1) antibodies in diagnosis and subtyping of CMML and in differentiating from other categories. Hypercellularity, high myeloid:erythroid ratio, increased proportion of 'myelo/monocytic' cells often seen as clusters and/or nodules, absence of eosinophilia, and presence of abnormal localisation of immature precursors (ALIP) and dysmegakaryopoiesis can aid in the diagnosis of CMML in BMTB. CD68 (PGM-1) positive cells amounted to 20.7 +/- 6.1% cells among CMML trephines. The proportion of CD34(+) cells among cases of CMML-1 was /=10% cells in two of three cases and 5% in the other case. Morphological and immunohistochemical features of BMTB samples are extremely helpful in the diagnosis of CMML.


Subject(s)
Leukemia, Myelomonocytic, Chronic/diagnosis , Aged , Aged, 80 and over , Antigens, CD34/analysis , Biomarkers, Tumor/analysis , Biopsy , Bone Marrow Cells/pathology , Bone Marrow Examination/methods , Diagnosis, Differential , Female , Humans , Hyperplasia/blood , Hyperplasia/diagnosis , Hyperplasia/pathology , Leukemia, Myelomonocytic, Chronic/blood , Leukemia, Myelomonocytic, Chronic/pathology , Male , Middle Aged , Polycythemia Vera/blood , Polycythemia Vera/diagnosis , Polycythemia Vera/pathology
7.
Br J Haematol ; 140(3): 279-86, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17973948

ABSTRACT

Acute myeloid leukaemia (AML) with multilineage dysplasia (MD) is one of the four main categories of AML in the World Health Organization (WHO) classification. The role of bone marrow trephine biopsy (BMTB) histology and immunohistochemistry in the diagnosis of AML-MD is currently unclear. BMTBs were studied in 11 cases of AML-MD and two cases of myelodysplasia that subsequently transformed to AML. Among them, six cases showed trilineage dysplasia and seven showed bilineage dysplasia. With respect to conforming to the WHO definition of AML, documentation of an increased proportion of immature myeloid cells was possible on morphology and counting of immature cells following immunostaining with CD34, CD117 or HLA-DR antibodies. Recognition and quantification of dysplastic features in the haemopoietic lineages was made easier by immunohistochemistry with antibodies to ret40f (glycophorin C), myeloperoxidase, CD61 and/or CD42b, CD34, CD117 and HLA-DR. Based on this relatively small series of cases we show the utility of BMTB and immunohistochemistry as an aid to the diagnosis of AML-MD. This has to be seen not just in light of its utility at diagnosis, but also the role the diagnostic BMTB would play for purposes of comparison when follow-up BMTBs are submitted in this group of patients.


Subject(s)
Bone Marrow Cells/pathology , Leukemia, Myeloid, Acute/pathology , Myelodysplastic Syndromes/pathology , Adult , Aged , Aged, 80 and over , Antigens, CD34/analysis , Biomarkers/analysis , Biopsy/methods , Bone Marrow Examination/methods , Cytogenetics , Disease Progression , Erythroblasts/pathology , Female , Humans , Immunohistochemistry , Immunophenotyping , Male , Megakaryocytes/pathology , Middle Aged , Myeloid Cells/pathology , Proto-Oncogene Proteins c-kit/analysis
9.
Arch Pathol Lab Med ; 131(7): 1130-4, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17617004

ABSTRACT

Enterocolic lymphocytic phlebitis (ELP) is a recently described entity and is of unknown etiology and pathogenesis. It is characterized by phlebitis of the bowel wall and mesentery, without arterial involvement or evidence of systemic vasculitis. The clinical presentation of ELP is varied, but it most commonly manifests with signs of an acute abdomen. Clinical, radiologic, and endoscopic findings are often conflicting and misdiagnosis is common as venous thrombosis is not suspected. The diagnosis of ELP is obtained histologically. There is a spectrum of histologic features associated with ELP, which includes lymphocytic phlebitis, necrotizing phlebitis, granulomatous phlebitis, and myointimal hyperplasia. Other features include venous thrombi and acute ischemic changes of the intestine. Surgical resection of the affected bowel is usually curative and recurrences are rare. The clinical and histopathologic features of ELP are reviewed.


Subject(s)
Intestinal Diseases/pathology , Intestines/blood supply , Phlebitis/pathology , Diagnosis, Differential , Humans , Intestinal Diseases/diagnosis , Lymphocytes/pathology , Phlebitis/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...